SCHEMBL5437137

SCHEMBL5437137

CCOc1ccc(Oc2ccc(S(=O)(=O)N3CCc4ccccc4C3OC(N)=O)cc2F)cc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.44
MAPT P10636 3/20 0.44
MMP1 P03956 1/20 0.42
SMN1; SMN2 Q16637 2/20 0.42
CA1 P00915 1/20 0.40
CA2 P00918 1/20 0.40
CA7 P43166 1/20 0.40
CA9 Q16790 1/20 0.40
CA14 Q9ULX7 1/20 0.40
ALOX5 P09917 1/20 0.39
AKR1C3 P42330 1/20 0.39
OXTR P30559 1/20 0.39
AVPR1A P37288 1/20 0.39
NPC1 O15118 1/20 0.38
RAB9A P51151 1/20 0.38
HDAC1 Q13547 1/20 0.38
HDAC2 Q92769 1/20 0.38
HDAC8 Q9BY41 1/20 0.38
KMT2A Q03164 2/20 0.38
PKM P14618 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5433930 1.00 LMNA (0.44) LMNAMAPTMMP1SMN1; SMN2CA1
SCHEMBL5443033 0.91 MMP1 (0.41) LMNAMAPTMMP1AKR1C3TAS2R14
SCHEMBL5433519 0.91 MMP1 (0.41) LMNAMAPTMMP1AKR1C3TAS2R14
SCHEMBL5439980 0.91 MMP1 (0.41) LMNAMAPTMMP1AKR1C3TAS2R14
SCHEMBL5164993 0.90 MMP1 (0.47) LMNAMAPTMMP1SMN1; SMN2ALOX5
SCHEMBL5165066 0.90 MMP1 (0.47) LMNAMAPTMMP1SMN1; SMN2ALOX5
SCHEMBL5443030 0.90 SMN1; SMN2 (0.44) LMNAMAPTMMP1SMN1; SMN2CA1
SCHEMBL5439640 0.89 MMP1 (0.50) LMNAMAPTMMP1SMN1; SMN2CA1
SCHEMBL5435833 0.89 MMP1 (0.50) LMNAMAPTMMP1SMN1; SMN2CA1
SCHEMBL5430809 0.89 MMP1 (0.50) LMNAMAPTMMP1SMN1; SMN2CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070203118-A1 SUBSTITUTED TETRAHYDROISOQUINOLINES USED IN THE FORM OF MMP INHIBITORS, METHOD FOR THE PRODUCTION AND USE THEREOF IN THE FORM OF DRUGS SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2007-08-30 US claimed
US-20070203118-A1 SUBSTITUTED TETRAHYDROISOQUINOLINES USED IN THE FORM OF MMP INHIBITORS, METHOD FOR THE PRODUCTION AND USE THEREOF IN THE FORM OF DRUGS SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2007-08-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070203118-A1 SUBSTITUTED TETRAHYDROISOQUINOLINES USED IN THE FORM OF MMP INHIBITORS, METHOD FOR THE PRODUCTION AND USE THEREOF IN THE FORM OF DRUGS MMP9, MMP2, MMP3 LMNA 601/4885MAPT 2019/4885MMP1 8/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.